Skip to main content
logo
Ilyang Pharmaceutical Co.,Ltd (KRX:007570)
South Korea flag South Korea · Delayed Price · Currency is KRW
8,070.00
-200.00 (-2.42%)
Sep 11, 2026, 3:30 PM KST

KRX:007570 Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
17,2936,9059,032-2,40919,38514,032
Depreciation & Amortization
8,4678,3449,82411,97111,76711,227
Other Amortization
-----14.99
Loss (Gain) From Sale of Assets
-39.84-89.729.54-0.51-21.22-2.86
Asset Writedown & Restructuring Costs
-54.5-45-2.49-40.5125.51-263.19
Loss (Gain) From Sale of Investments
-272.418-27.43-30.5724.78-
Loss (Gain) on Equity Investments
1,593843.99-2,08313,425-10,754-9,236
Provision & Write-off of Bad Debts
2,494270.6-52.33-393.8-964.921,067
Other Operating Activities
2,3122,5602,4813,6042,42716,825
Change in Accounts Receivable
566.15-325.451,282-1,0873,101-10,261
Change in Inventory
-2,254-7,550-7,606-5,574-16,8305,719
Change in Accounts Payable
-1,065-1,938-3,545-3,4256,5024,160
Change in Other Net Operating Assets
5,4503,057-3,696-1,421-8,77918,147
Operating Cash Flow
34,48912,0415,61514,6195,88351,429
Operating Cash Flow Growth
-114.44%-61.59%148.49%-88.56%-10.53%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-6,162-5,717-38,200-5,883-3,946-12,371
Sale of Property, Plant & Equipment
-026.97-0.52200.92
Sale (Purchase) of Intangibles
-4,875-4,547-2,423-949.74-12.08-2,128
Investment in Securities
5,8673,0023,365-4,60628,115-565.4
Other Investing Activities
0.310.382.53-77.65-14366.7
Investing Cash Flow
-5,171-7,225-37,175-11,51624,163-14,671

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-29,91168,71624,78935,00039,147
Long-Term Debt Issued
-15,3008,7006,000--
Total Debt Issued
31,36945,21177,41630,78935,00039,147
Short-Term Debt Repaid
--26,200-42,000-30,000-56,500-31,147
Long-Term Debt Repaid
--542.1-717.18-2,753-3,737-10,758
Total Debt Repaid
-50,649-26,742-42,717-32,753-60,237-41,905
Net Debt Issued (Repaid)
-19,28018,46934,699-1,965-25,237-2,758
Issuance of Common Stock
--515.48---
Repurchase of Common Stock
--1,000--2,000-3,000-
Dividends Paid
-3,262-2,881-2,974-2,992-3,942-2,350
Other Financing Activities
-87.428.6-0.56-22183.5-31,524
Financing Cash Flow
-22,62914,61732,240-6,978-31,996-36,632

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
530.68-74.22201.72115.33-164.64-
Miscellaneous Cash Flow Adjustments
0-----
Net Cash Flow
7,22019,359881.17-3,759-2,115125.49

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
28,3266,323-32,5858,7361,93839,057
Free Cash Flow Growth
---350.88%-95.04%-17.44%
Free Cash Flow Margin
10.19%2.32%-12.13%3.28%0.78%16.11%
Free Cash Flow Per Share
1629.00352.33-1767.81484.85106.902145.40
Levered Free Cash Flow
2,076203.66-37,22010,211-1,03734,080
Unlevered Free Cash Flow
3,8862,098-35,38812,227295.8635,249

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
3,8964,0403,6343,3122,0961,912
Cash Income Tax Paid
7,0916,7751,5981,2395,1081,320
Change in Working Capital
2,697-6,756-13,566-11,507-16,00617,765